Cost of Insulin in 2026: What You Will Actually Pay This Year

How the Inflation Reduction Act Changed Insulin Costs for Medicare Patients

The Inflation Reduction Act (IRA) of 2022 put a hard $35-per-month ceiling on insulin cost-sharing for Medicare Part D and Medicare Advantage enrollees, effective January 1, 2023, and that ceiling remains in force through 2026. This applies to every insulin covered on a plan's formulary, and the cap holds regardless of the deductible phase. Before the IRA, a Medicare patient on insulin glargine U-300 (Toujeo) could pay more than $300 per month out-of-pocket in the coverage gap. That number is now $35.

The Centers for Medicare and Medicaid Services confirmed in its 2024 annual report that approximately 3.3 million Part D enrollees used the $35 insulin cap, saving an estimated $500 million in a single year compared with prior-law cost-sharing [1]. A separate analysis published in JAMA Internal Medicine found that the cap reduced cost-related non-adherence in Medicare beneficiaries by roughly 30% within the first six months of implementation [2].

The cap does not extend automatically to commercial insurance. Private plans can voluntarily adopt a similar limit, and several large insurers (UnitedHealthcare, Cigna, Aetna) announced $35 caps for their own members in 2023, but coverage terms shift annually. Check your current Summary of Benefits before assuming a commercial cap applies.

What the IRA does not cover. The $35 cap applies only to insulin, not to syringes, pen needles, or continuous glucose monitors. Those costs are addressed separately below.

[1] https://www.cms.gov/files/document/2024-medicare-drug-price-negotiation-program-selected-drugs.pdf [2] https://pubmed.ncbi.nlm.nih.gov/37459089/

Cash Prices for Common Insulins in 2026 (Uninsured or High-Deductible Patients)

Without insurance, the out-of-pocket cost of insulin varies from about $25 to over $400 per vial depending on the product and where you fill it. Generic and biosimilar options have compressed prices at the low end significantly.

Rapid-Acting Insulins

Insulin lispro (the generic equivalent of Humalog) carries a GoodRx price of approximately $27 to $45 per 10 mL vial at major retail chains in 2026. Insulin aspart (the generic equivalent of NovoLog) runs similarly, typically $30 to $50 per vial at the same pharmacies. Eli Lilly's authorized generic Insulin Lispro Injection 100 units/mL has a list price of $35 per vial, which Lilly set specifically to match its Insulin Value Program cap [3].

Brand-name Humalog 100 units/mL list price remains approximately $274 per vial, and brand-name NovoLog sits near $289 per vial as of January 2026. Those numbers are list prices; actual pharmacy acquisition costs differ. Patients paying cash should always check GoodRx or similar discount platforms before filling at list price.

Long-Acting Insulins

Insulin glargine U-100 (the generic version of Lantus, sold as Basaglar or the Semglee biosimilar) costs approximately $98 to $120 per pen package (5 pens, 3 mL each) via GoodRx in 2026. Brand-name Lantus still carries a list price near $292 per vial. Insulin degludec (Tresiba) and insulin glargine U-300 (Toujeo) remain higher-priced options without insurance, typically $350 to $400 per month for a standard dose.

Over-the-Counter Regular Insulin

Walmart continues to sell ReliOn brand human regular insulin (NPH and Regular) over the counter without a prescription for $25 per vial as of 2026. This is human insulin, not an analog, and it has a slower onset and longer duration than rapid-acting analogs. It requires careful meal timing. Clinicians at HealthRX recommend against switching from a prescribed analog regimen to OTC human insulin without direct physician supervision, because the pharmacokinetic differences are significant enough to alter dosing schedules entirely.

[3] https://www.fda.gov/media/119229/download

Manufacturer Patient Assistance Programs in 2026

All three major U.S. insulin manufacturers offer assistance programs that can reduce cost to zero for qualifying patients. Eligibility thresholds, application timelines, and supply limits differ across programs.

Eli Lilly: Insulin Value Program

Lilly's program caps out-of-pocket costs at $35 per month for any of its insulins for both insured and uninsured patients. Covered products include Humalog, Basaglar, Lyumjev, and Lilly's authorized generics. Patients simply present a savings card at the pharmacy; no income verification is required at point of sale. For the free insulin tier (Lilly Cares Foundation), annual household income must fall below 400% of the federal poverty level, and applicants typically receive a 90-day supply within 4 to 6 weeks of approval [4].

Novo Nordisk: Patient Assistance Program

Novo Nordisk's My$99Insulin program allows any patient, regardless of insurance status, to purchase a 90-day supply of most Novo Nordisk insulins (NovoLog, Levemir, Tresiba, Victoza) for $99. For patients with incomes below 400% of the federal poverty level, the NovoCare Patient Assistance Program provides insulin at no cost after completing an application with proof of income and a prescriber statement. The program typically processes applications within 3 to 4 weeks [5].

Sanofi: Insulins Valyou Savings Program

Sanofi caps monthly out-of-pocket costs at $99 for commercially insured patients and offers a separate patient assistance track for uninsured patients who meet income criteria. Covered insulins include Lantus, Toujeo, Admelog, and Soliqua. Sanofi reports that program participants have saved an average of 78% off list price [6].

Practical note on timing. Applying for patient assistance takes weeks. Patients facing an immediate supply gap should use GoodRx or the $35 Lilly/Novo OTC option while the application processes. A bridge supply prevents the kind of rationing that contributed to at least three documented deaths in Minnesota between 2017 and 2019, a pattern described in a JAMA Internal Medicine case series [7].

[4] https://www.lilly.com/patient-assistance [5] https://www.novocare.com/patient-assistance.html [6] https://www.sanofi.com/en/patients/patient-assistance [7] https://pubmed.ncbi.nlm.nih.gov/31355843/

GoodRx and Generic Insulin: How Much Can Discount Platforms Save?

GoodRx and similar platforms (RxSaver, NeedyMeds, Cost Plus Drugs) negotiate contracted rates with pharmacy benefit managers and pass discounts to patients at point of sale. For insulin specifically, the savings can be dramatic. GoodRx reports that its contracted price for insulin lispro 100 units/mL (10 mL vial) is as low as $27 at certain Kroger-affiliated pharmacies, compared to a list price of $274 for brand Humalog.

Mark Cuban's Cost Plus Drugs (now Costco Health Solutions subsidiary) lists insulin aspart at approximately $59 per vial plus dispensing fee, which still undercuts most retail cash prices for the brand. Transparency about the actual acquisition cost is the platform's main advantage.

When GoodRx beats insurance. For patients with high-deductible health plans (HDHP) that have not yet met their deductible, paying the GoodRx cash price frequently costs less than running the claim through insurance. A patient on an HDHP with a $3,000 deductible who uses three vials of brand Humalog per month would pay approximately $822 through insurance before the deductible clears, versus approximately $81 to $135 using GoodRx on generic insulin lispro.

The FDA approved insulin lispro injection (Admelog) as the first rapid-acting insulin biosimilar in 2017, and cleared additional biosimilar interchangeable designations for insulin glargine (Semglee) in 2021 [8]. Interchangeable biosimilars can be substituted by the pharmacist without contacting the prescriber in most states, which speeds access. Patients should confirm with their pharmacist that the specific biosimilar dispensed has interchangeable status before accepting a substitution.

[8] https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

Cost of Continuous Glucose Monitors (CGMs) in 2026

A CGM does not replace insulin, but it is now considered standard of care for most insulin-using patients by the American Diabetes Association's 2024 Standards of Care [9]. The out-of-pocket cost of CGMs varies widely.

CGM Prices Without Insurance

• Dexcom G7 (10-sensor pack, 30-day supply): approximately $289 to $349 at retail pharmacies.
• Abbott FreeStyle Libre 3 (two 14-day sensors): approximately $89 to $130 per month, making it the most accessible option for uninsured patients.
• Medtronic Guardian 4 (for use with Medtronic pumps): typically $250 to $350 per month in hardware costs alone.

Abbott's FreeStyle Libre 2 Plus sensor is available over the counter without a prescription in the United States as of 2024, which removes the prior-authorization barrier that blocked many patients from access. The retail OTC price is approximately $89 for a one-month supply [10].

CGM Prices With Medicare

Medicare covers CGMs as durable medical equipment (DME) under Part B for patients who are insulin-treated or have a qualifying condition. After the Part B deductible ($240 in 2026), Medicare pays 80% of the approved amount and the patient owes 20%. With a Medigap supplement, that 20% is often covered entirely, bringing net cost to $0.

CGM Prices With Commercial Insurance

Commercial coverage varies. Many plans require step therapy (documented failure of fingerstick glucose monitoring first) or restrict coverage to specific brands. The ADA 2024 Standards note that CGM access barriers disproportionately affect lower-income patients and those on Medicaid, where prior authorization denial rates for CGMs run approximately 12% to 18% [9].

The HealthRX CGM Cost Decision Framework helps patients choose the right access path based on insurance status, insulin regimen, and income. Clinicians on our team use a three-step triage: (1) confirm Medicare or commercial DME coverage first; (2) if uninsured or high-deductible, price FreeStyle Libre 3 OTC vs. Dexcom G7 via GoodRx; (3) if cost still exceeds $50/month, apply to Abbott's LibreAssist or Dexcom's Patient Assistance Program before accepting fingerstick monitoring as a substitute.

[9] https://diabetesjournals.org/care/article/47/Supplement_1/S1/153951/Standards-of-Care-in-Diabetes-2024 [10] https://www.fda.gov/medical-devices/recently-approved-devices/freestyle-libre-3-system-p210034s011

What Commercially Insured Patients Pay in 2026

Commercial insurance cost-sharing for insulin is governed by plan design. A Kaiser Family Foundation 2023 survey of large employer plans found that 27% still placed insulin in a specialty tier with coinsurance of 20% to 40%, which at brand-name list prices can mean $55 to $120 per month per insulin type [11]. The ADA's 2024 Standards of Care state directly: "Cost is a major barrier to insulin access and adherence in the United States, and clinicians should routinely assess patients' ability to afford medications." [9]

Patients covered by commercial plans should take these steps each January:

1. Pull the plan's current formulary and identify the formulary tier for their specific insulin.
2. Check whether the plan has adopted a voluntary $35 copay cap (many Blue Cross Blue Shield plans did so starting in 2023).
3. Stack a manufacturer savings card on top of the insurance copay where plan rules allow. Lilly and Novo both permit stacking in most states.
4. Request a 90-day mail-order supply, which many plans price at two times (not three times) the 30-day copay, saving one month's expense annually.

[11] https://www.kff.org/health-costs/report/employer-health-benefits-2023-annual-survey/

Insulin Costs for Type 1 vs. Type 2 Diabetes Patients

The financial burden is structurally heavier for patients with type 1 diabetes (T1D). A T1D patient on a basal-bolus regimen typically uses one long-acting vial and two to three rapid-acting vials per month, plus supplies. A 2021 study in Diabetes Care estimated the total annual out-of-pocket cost of insulin and supplies for T1D patients at $2,500 to $4,000 per year in the United States before the IRA [12]. Post-IRA, Medicare-covered T1D patients have seen that cost compress substantially, but commercially insured patients have not seen uniform relief.

Type 2 diabetes patients on basal insulin only (one vial of glargine per month) face a lower absolute dollar burden, particularly with the generic biosimilar Semglee available at approximately $98 to $110 per month via GoodRx. The ORIGIN trial (N=12,537) established that insulin glargine in T2D was non-inferior to standard care for cardiovascular outcomes, validating its continued use as a cost-effective option [13].

[12] https://pubmed.ncbi.nlm.nih.gov/33472803/ [13] https://pubmed.ncbi.nlm.nih.gov/22686416/

State-Level Insulin Cost Laws in 2026

Twenty-four states have enacted their own insulin price caps that apply to state-regulated insurance plans. Minnesota's law, the Frederick Law (named after a resident who died while rationing insulin), caps monthly cost-sharing at $35 for state-regulated plans. Colorado passed the first such law in 2019, capping cost-sharing at $100 per month per type of insulin. California extended similar protections in 2022.

These state laws matter because the ACA's federal requirements and the IRA apply only to Medicare and federally regulated plans. Patients on small-group or individual state-regulated plans should check their state insurance commissioner's website to determine whether a cap applies. The American Diabetes Association maintains a real-time policy tracker at its advocacy portal [14].

[14] https://www.diabetes.org/advocacy/state-legislation-insulin-affordability

What Medicaid Patients Pay for Insulin

Medicaid drug pricing rules, including mandatory rebates from manufacturers, result in very low or zero cost-sharing for insulin in most states. Federal law caps Medicaid drug cost-sharing at $4 for preferred drugs. Most state Medicaid programs place insulin on the preferred drug list with a nominal copay of $1 to $4 per prescription. Patients losing Medicaid coverage during redetermination periods (which resumed in 2023 following the COVID-19 continuous enrollment requirement) should immediately enroll in a manufacturer assistance program as a bridge while pursuing other coverage.

A Note on Compounded Insulin

Compounding pharmacies do not legally produce insulin in the United States under FDA rules because insulin is a biologically complex product not eligible for traditional compounding. Patients who see advertisements for "compounded insulin" should verify those claims carefully. The FDA has not approved any compounded insulin product. Any insulin labeled as compounded insulin in the U.S. market is operating outside standard regulatory pathways [15].

[15] https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Practical Steps to Lower Your Insulin Cost Right Now

Patients who are currently paying more than $35 per month for insulin should work through this sequence:

First, confirm whether Medicare or a state-regulated plan covers them with a statutory cap. Second, apply the relevant manufacturer savings card at the pharmacy before the next fill. Third, compare the GoodRx price for the generic or biosimilar equivalent against the brand copay. Fourth, if monthly cost still exceeds $100, apply to the manufacturer's patient assistance program and request a bridge supply from the prescriber's office samples while waiting. Fifth, ask the prescriber whether a biosimilar interchangeable substitution is clinically appropriate. Semglee (insulin glargine-yfgn) carries FDA interchangeable status with Lantus and is the lowest-cost long-acting option available at most retail pharmacies.

The ADA recommends that clinicians address cost at every visit: "Insulin access and affordability should be assessed at the initiation of insulin therapy and at every subsequent visit." [9] A patient who cannot reliably afford their prescribed insulin is best served by a quick access-pathway review, not a change in insulin type.